CANCER:

Gastrointestinal Cancer

News alerts, weekly reports and conference planners

No biomarker	Gastroesophageal Junction Adenocarcinoma	No biomarker	Gastroesophageal Junction Adenocarcinoma	nivolumab Sensitive: A1 - Approval Int J Cancer - 1 week (New B) nivolumab Sensitive : A1 Int J Cancer - 1wk	nivolumab Sensitive: A1 - Approval Int J Cancer - 1 week nivolumab Sensitive : A1 Int J Cancer - 1 week - (New B)
No biomarker	Esophageal Adenocarcinoma	No biomarker	Esophageal Adenocarcinoma	nivolumab Sensitive: A1 - Approval Int J Cancer - 1 week (New B) nivolumab Sensitive : A1 Int J Cancer - 1wk	nivolumab Sensitive: A1 - Approval Int J Cancer - 1 week nivolumab Sensitive : A1 Int J Cancer - 1 week - (New B)
No biomarker	Gastric Cancer	No biomarker	Gastric Cancer	nivolumab Sensitive: A1 - Approval Int J Cancer - 1 week (New B) nivolumab Sensitive : A1 Int J Cancer - 1wk	nivolumab Sensitive: A1 - Approval Int J Cancer - 1 week nivolumab Sensitive : A1 Int J Cancer - 1 week - (New B)
FGFR2 rearrangement	Cholangiocarcinoma	FGFR2 rearrangement	Cholangiocarcinoma	pemigatinib Sensitive: A1 - Approval PRNewswire - 1 week (New A1) pemigatinib Sensitive : A1 PRNewswire - 1wk	pemigatinib Sensitive: A1 - Approval PRNewswire - 1 week pemigatinib Sensitive : A1 PRNewswire - 1 week - (New A1)
FGFR2 fusion	Cholangiocarcinoma	FGFR2 fusion	Cholangiocarcinoma	pemigatinib Sensitive: A1 - Approval PRNewswire - 1 week (New A1) pemigatinib Sensitive : A1 PRNewswire - 1wk	pemigatinib Sensitive: A1 - Approval PRNewswire - 1 week pemigatinib Sensitive : A1 PRNewswire - 1 week - (New A1)
HER-2 positive	Colorectal Cancer	HER-2 positive	Colorectal Cancer	trastuzumab + tucatinib Sensitive: B - Late Trials Seagen Press Release - 1 week (New B) trastuzumab + tucatinib Sensitive : B Seagen Press Release - 1wk	trastuzumab + tucatinib Sensitive: B - Late Trials Seagen Press Release - 1 week trastuzumab + tucatinib Sensitive : B Seagen Press Release - 1 week - (New B)
ARID1A mutation	Colorectal Cancer	ARID1A mutation	Colorectal Cancer	cetuximab Resistant: C3 – Early Trials Nat Commun - 1 week (New C3) cetuximab Resistant : C3 Nat Commun - 1wk	cetuximab Resistant: C3 – Early Trials Nat Commun - 1 week cetuximab Resistant : C3 Nat Commun - 1 week - (New C3)
CPEB1 underexpression	Gastric Adenocarcinoma	CPEB1 underexpression	Gastric Adenocarcinoma	5-fluorouracil Sensitive: C3 – Early Trials J Gastrointest Oncol - 2 weeks (New C3) 5-fluorouracil Sensitive : C3 J Gastrointest Oncol - 2wk	5-fluorouracil Sensitive: C3 – Early Trials J Gastrointest Oncol - 2 weeks 5-fluorouracil Sensitive : C3 J Gastrointest Oncol - 2 weeks - (New C3)
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval ESMO 2022 - 3 weeks (New C3) fam-trastuzumab deruxtecan-nxki Sensitive : A1 ESMO 2022 - 3wk	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval ESMO 2022 - 3 weeks fam-trastuzumab deruxtecan-nxki Sensitive : A1 ESMO 2022 - 3 weeks - (New C3)
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval ESMO 2022 - 3 weeks (New C3) fam-trastuzumab deruxtecan-nxki Sensitive : A1 ESMO 2022 - 3wk	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval ESMO 2022 - 3 weeks fam-trastuzumab deruxtecan-nxki Sensitive : A1 ESMO 2022 - 3 weeks - (New C3)
BRCA2 mutation	Pancreatic Cancer	BRCA2 mutation	Pancreatic Cancer	olaparib Sensitive: A1 - Approval ESMO 2022 - 3 weeks (New C3) olaparib Sensitive : A1 ESMO 2022 - 3wk	olaparib Sensitive: A1 - Approval ESMO 2022 - 3 weeks olaparib Sensitive : A1 ESMO 2022 - 3 weeks - (New C3)
BRCA1 mutation	Pancreatic Cancer	BRCA1 mutation	Pancreatic Cancer	olaparib Sensitive: A1 - Approval ESMO 2022 - 3 weeks (New C3) olaparib Sensitive : A1 ESMO 2022 - 3wk	olaparib Sensitive: A1 - Approval ESMO 2022 - 3 weeks olaparib Sensitive : A1 ESMO 2022 - 3 weeks - (New C3)
BRAF V600E	Colorectal Cancer	BRAF V600E	Colorectal Cancer	cetuximab + encorafenib + binimetinib Sensitive: A1 - Approval ESMO 2022 - 3 weeks (New C3) cetuximab + encorafenib + binimetinib Sensitive : A1 ESMO 2022 - 3wk	cetuximab + encorafenib + binimetinib Sensitive: A1 - Approval ESMO 2022 - 3 weeks cetuximab + encorafenib + binimetinib Sensitive : A1 ESMO 2022 - 3 weeks - (New C3)
No biomarker	Biliary Tract Cancer	No biomarker	Biliary Tract Cancer	durvalumab Sensitive: A1 - Approval FDA - 3 weeks (New A1) durvalumab Sensitive : A1 FDA - 3wk	durvalumab Sensitive: A1 - Approval FDA - 3 weeks durvalumab Sensitive : A1 FDA - 3 weeks - (New A1)
MSI-H/dMMR	Colon Cancer	MSI-H/dMMR	Colon Cancer	nivolumab + ipilimumab Sensitive: A2 - Guideline ESMO 2022 - 3 weeks (New C3) nivolumab + ipilimumab Sensitive : A2 ESMO 2022 - 3wk	nivolumab + ipilimumab Sensitive: A2 - Guideline ESMO 2022 - 3 weeks nivolumab + ipilimumab Sensitive : A2 ESMO 2022 - 3 weeks - (New C3)
RAS wild-type	Colorectal Cancer	RAS wild-type	Colorectal Cancer	cetuximab Sensitive: B - Late Trials ESMO 2022 - 3 weeks (New C3) cetuximab Sensitive : B ESMO 2022 - 3wk	cetuximab Sensitive: B - Late Trials ESMO 2022 - 3 weeks cetuximab Sensitive : B ESMO 2022 - 3 weeks - (New C3)
MSI-H/dMMR	Gastrointestinal Cancer	MSI-H/dMMR	Gastrointestinal Cancer	dostarlimab Sensitive: C1 - Off-label ESMO 2022 - 3 weeks (New C3) dostarlimab Sensitive : C1 ESMO 2022 - 3wk	dostarlimab Sensitive: C1 - Off-label ESMO 2022 - 3 weeks dostarlimab Sensitive : C1 ESMO 2022 - 3 weeks - (New C3)
PD-L1 expression	Esophageal Squamous Cell Carcinoma	PD-L1 expression	Esophageal Squamous Cell Carcinoma	atezolizumab Sensitive: C1 - Off-label ESMO 2022 - 3 weeks (New C3) atezolizumab Sensitive : C1 ESMO 2022 - 3wk	atezolizumab Sensitive: C1 - Off-label ESMO 2022 - 3 weeks atezolizumab Sensitive : C1 ESMO 2022 - 3 weeks - (New C3)
FGFR2 fusion	Cholangiocarcinoma	FGFR2 fusion	Cholangiocarcinoma	ARQ 087 Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks (New C3) ARQ 087 Sensitive : C2 ESMO 2022 - 3wk	ARQ 087 Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks ARQ 087 Sensitive : C2 ESMO 2022 - 3 weeks - (New C3)
KRAS G12C	Colorectal Cancer	KRAS G12C	Colorectal Cancer	MRTX849 Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks (New C3) MRTX849 Sensitive : C2 ESMO 2022 - 3wk	MRTX849 Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks MRTX849 Sensitive : C2 ESMO 2022 - 3 weeks - (New C3)
FGFR2 amplification	Cholangiocarcinoma	FGFR2 amplification	Cholangiocarcinoma	ARQ 087 Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks (New C3) ARQ 087 Sensitive : C2 ESMO 2022 - 3wk	ARQ 087 Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks ARQ 087 Sensitive : C2 ESMO 2022 - 3 weeks - (New C3)
MSI-H/dMMR	Colorectal Cancer	MSI-H/dMMR	Colorectal Cancer	avelumab Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks (New C3) avelumab Sensitive : C2 ESMO 2022 - 3wk	avelumab Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks avelumab Sensitive : C2 ESMO 2022 - 3 weeks - (New C3)
RAS wild-type	Colorectal Cancer	RAS wild-type	Colorectal Cancer	cetuximab + avelumab Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks (New C3) cetuximab + avelumab Sensitive : C2 ESMO 2022 - 3wk	cetuximab + avelumab Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks cetuximab + avelumab Sensitive : C2 ESMO 2022 - 3 weeks - (New C3)
KRAS G12C	Colorectal Cancer	KRAS G12C	Colorectal Cancer	RG6330 Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks (New C3) RG6330 Sensitive : C2 ESMO 2022 - 3wk	RG6330 Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks RG6330 Sensitive : C2 ESMO 2022 - 3 weeks - (New C3)
BRAF V600	Colorectal Cancer	BRAF V600	Colorectal Cancer	FORE-8394 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) FORE-8394 Sensitive : C3 ESMO 2022 - 3wk	FORE-8394 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks FORE-8394 Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
KRAS G12C	Colorectal Cancer	KRAS G12C	Colorectal Cancer	cetuximab + MRTX849 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) cetuximab + MRTX849 Sensitive : C3 ESMO 2022 - 3wk	cetuximab + MRTX849 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks cetuximab + MRTX849 Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
KRAS G12C	Colorectal Cancer	KRAS G12C	Colorectal Cancer	panitumumab + sotorasib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) panitumumab + sotorasib Sensitive : C3 ESMO 2022 - 3wk	panitumumab + sotorasib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks panitumumab + sotorasib Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	bevacizumab + PCM-075 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) bevacizumab + PCM-075 Sensitive : C3 ESMO 2022 - 3wk	bevacizumab + PCM-075 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks bevacizumab + PCM-075 Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
KRAS G12C	Colorectal Cancer	KRAS G12C	Colorectal Cancer	bevacizumab Resistant: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) bevacizumab Resistant : C3 ESMO 2022 - 3wk	bevacizumab Resistant: C3 – Early Trials ESMO 2022 - 3 weeks bevacizumab Resistant : C3 ESMO 2022 - 3 weeks - (New C3)
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	KN046 + KN026 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) KN046 + KN026 Sensitive : C3 ESMO 2022 - 3wk	KN046 + KN026 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks KN046 + KN026 Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	KN046 + KN026 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) KN046 + KN026 Sensitive : C3 ESMO 2022 - 3wk	KN046 + KN026 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks KN046 + KN026 Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
BRAF V600	Pancreatic Cancer	BRAF V600	Pancreatic Cancer	FORE-8394 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) FORE-8394 Sensitive : C3 ESMO 2022 - 3wk	FORE-8394 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks FORE-8394 Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
CEACAM5 overexpression	Gastric Cancer	CEACAM5 overexpression	Gastric Cancer	SAR408701 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) SAR408701 Sensitive : C3 ESMO 2022 - 3wk	SAR408701 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks SAR408701 Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
HER-2 amplification + KRAS exon 2 wild-type	Colorectal Cancer	HER-2 amplification + KRAS exon 2 wild-type	Colorectal Cancer	trastuzumab + lapatinib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) trastuzumab + lapatinib Sensitive : C3 ESMO 2022 - 3wk	trastuzumab + lapatinib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks trastuzumab + lapatinib Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
RAS wild-type + BRAF wild-type	Colorectal Cancer	RAS wild-type + BRAF wild-type	Colorectal Cancer	nivolumab + ipilimumab + regorafenib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) nivolumab + ipilimumab + regorafenib Sensitive : C3 ESMO 2022 - 3wk	nivolumab + ipilimumab + regorafenib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks nivolumab + ipilimumab + regorafenib Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
GemPred signature	Pancreatic Adenocarcinoma	GemPred signature	Pancreatic Adenocarcinoma	gemcitabine Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) gemcitabine Sensitive : C3 ESMO 2022 - 3wk	gemcitabine Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks gemcitabine Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
HRD signature	Pancreatic Cancer	HRD signature	Pancreatic Cancer	FOLFIRINOX Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) FOLFIRINOX Sensitive : C3 ESMO 2022 - 3wk	FOLFIRINOX Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks FOLFIRINOX Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
PD-1 expression + CD8 expression	Esophageal Squamous Cell Carcinoma	PD-1 expression + CD8 expression	Esophageal Squamous Cell Carcinoma	atezolizumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) atezolizumab Sensitive : C3 ESMO 2022 - 3wk	atezolizumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks atezolizumab Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
CD8 expression	Esophageal Squamous Cell Carcinoma	CD8 expression	Esophageal Squamous Cell Carcinoma	atezolizumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) atezolizumab Sensitive : C3 ESMO 2022 - 3wk	atezolizumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks atezolizumab Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
PD-1 expression	Esophageal Squamous Cell Carcinoma	PD-1 expression	Esophageal Squamous Cell Carcinoma	nivolumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) nivolumab Sensitive : C3 ESMO 2022 - 3wk	nivolumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks nivolumab Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
HER-2 negative	Gastroesophageal Junction Adenocarcinoma	HER-2 negative	Gastroesophageal Junction Adenocarcinoma	nivolumab + regorafenib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) nivolumab + regorafenib Sensitive : C3 ESMO 2022 - 3wk	nivolumab + regorafenib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks nivolumab + regorafenib Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
ITGAM overexpression + LAG3 overexpression	Gastric Cancer	ITGAM overexpression + LAG3 overexpression	Gastric Cancer	nivolumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) nivolumab Sensitive : C3 ESMO 2022 - 3wk	nivolumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks nivolumab Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
ITGAM overexpression + CTLA4 overexpression	Gastric Cancer	ITGAM overexpression + CTLA4 overexpression	Gastric Cancer	nivolumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) nivolumab Sensitive : C3 ESMO 2022 - 3wk	nivolumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks nivolumab Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
PD-1 expression	Gastroesophageal Junction Adenocarcinoma	PD-1 expression	Gastroesophageal Junction Adenocarcinoma	atezolizumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) atezolizumab Sensitive : C3 ESMO 2022 - 3wk	atezolizumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks atezolizumab Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
PD-1 expression	Gastric Cancer	PD-1 expression	Gastric Cancer	atezolizumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) atezolizumab Sensitive : C3 ESMO 2022 - 3wk	atezolizumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks atezolizumab Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
EGFR expression + HER-2 expression	Gastric Cancer	EGFR expression + HER-2 expression	Gastric Cancer	ASLAN001 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) ASLAN001 Sensitive : C3 ESMO 2022 - 3wk	ASLAN001 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks ASLAN001 Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
PD-1 expression	Gastroesophageal Junction Adenocarcinoma	PD-1 expression	Gastroesophageal Junction Adenocarcinoma	nivolumab + ipilimumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) nivolumab + ipilimumab Sensitive : C3 ESMO 2022 - 3wk	nivolumab + ipilimumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks nivolumab + ipilimumab Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
SLFN11 expression	Esophageal Squamous Cell Carcinoma	SLFN11 expression	Esophageal Squamous Cell Carcinoma	cisplatin + 5-fluorouracil Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) cisplatin + 5-fluorouracil Sensitive : C3 ESMO 2022 - 3wk	cisplatin + 5-fluorouracil Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks cisplatin + 5-fluorouracil Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
RAS wild-type	Colorectal Cancer	RAS wild-type	Colorectal Cancer	trastuzumab + tucatinib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) trastuzumab + tucatinib Sensitive : C3 ESMO 2022 - 3wk	trastuzumab + tucatinib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks trastuzumab + tucatinib Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
IDH1 R132C + PIK3CA E545K + IDH2 R172K	Cholangiocarcinoma	IDH1 R132C + PIK3CA E545K + IDH2 R172K	Cholangiocarcinoma	ivosidenib Resistant: C4 – Case Studies NPJ Precis Oncol - 3 weeks (New C4) ivosidenib Resistant : C4 NPJ Precis Oncol - 3wk	ivosidenib Resistant: C4 – Case Studies NPJ Precis Oncol - 3 weeks ivosidenib Resistant : C4 NPJ Precis Oncol - 3 weeks - (New C4)
FGFR2 M540_I541insMM	Cholangiocarcinoma	FGFR2 M540_I541insMM	Cholangiocarcinoma	pemigatinib Sensitive: C4 – Case Studies Target Oncol - 3 weeks (New C4) pemigatinib Sensitive : C4 Target Oncol - 3wk	pemigatinib Sensitive: C4 – Case Studies Target Oncol - 3 weeks pemigatinib Sensitive : C4 Target Oncol - 3 weeks - (New C4)
MSI-H/dMMR	Small Intestinal Carcinoma	MSI-H/dMMR	Small Intestinal Carcinoma	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	trastuzumab Sensitive: A1 - Approval trastuzumab Sensitive : A1	trastuzumab Sensitive: A1 - Approval trastuzumab Sensitive : A1
No biomarker	Esophageal Cancer	No biomarker	Esophageal Cancer	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Esophageal Squamous Cell Carcinoma	No biomarker	Esophageal Squamous Cell Carcinoma	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Gastric Adenocarcinoma	No biomarker	Gastric Adenocarcinoma	cisplatin + 5-fluorouracil + docetaxel Sensitive: A1 - Approval cisplatin + 5-fluorouracil + docetaxel Sensitive : A1	cisplatin + 5-fluorouracil + docetaxel Sensitive: A1 - Approval cisplatin + 5-fluorouracil + docetaxel Sensitive : A1
No biomarker	Gastroesophageal Junction Adenocarcinoma	No biomarker	Gastroesophageal Junction Adenocarcinoma	cisplatin + 5-fluorouracil + docetaxel Sensitive: A1 - Approval cisplatin + 5-fluorouracil + docetaxel Sensitive : A1	cisplatin + 5-fluorouracil + docetaxel Sensitive: A1 - Approval cisplatin + 5-fluorouracil + docetaxel Sensitive : A1
PD-L1 expression	Esophageal Squamous Cell Carcinoma	PD-L1 expression	Esophageal Squamous Cell Carcinoma	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Hepatocellular Cancer	No biomarker	Hepatocellular Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
No biomarker	Hepatocellular Cancer	No biomarker	Hepatocellular Cancer	bevacizumab + atezolizumab Sensitive: A1 - Approval bevacizumab + atezolizumab Sensitive : A1	bevacizumab + atezolizumab Sensitive: A1 - Approval bevacizumab + atezolizumab Sensitive : A1
FGFR2 rearrangement	Cholangiocarcinoma	FGFR2 rearrangement	Cholangiocarcinoma	infigratinib Sensitive: A1 - Approval infigratinib Sensitive : A1	infigratinib Sensitive: A1 - Approval infigratinib Sensitive : A1
FGFR2 fusion	Cholangiocarcinoma	FGFR2 fusion	Cholangiocarcinoma	infigratinib Sensitive: A1 - Approval infigratinib Sensitive : A1	infigratinib Sensitive: A1 - Approval infigratinib Sensitive : A1
IDH1 mutation	Cholangiocarcinoma	IDH1 mutation	Cholangiocarcinoma	ivosidenib Sensitive: A1 - Approval ivosidenib Sensitive : A1	ivosidenib Sensitive: A1 - Approval ivosidenib Sensitive : A1
MSI-H/dMMR	Colorectal Cancer	MSI-H/dMMR	Colorectal Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
MSI-H/dMMR	Colorectal Cancer	MSI-H/dMMR	Colorectal Cancer	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
No biomarker	Gastric Cancer	No biomarker	Gastric Cancer	TPF Sensitive: A1 - Approval TPF Sensitive : A1	TPF Sensitive: A1 - Approval TPF Sensitive : A1
No biomarker	Gastroesophageal Junction Adenocarcinoma	No biomarker	Gastroesophageal Junction Adenocarcinoma	TPF Sensitive: A1 - Approval TPF Sensitive : A1	TPF Sensitive: A1 - Approval TPF Sensitive : A1
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	pembrolizumab + trastuzumab Sensitive: A1 - Approval pembrolizumab + trastuzumab Sensitive : A1	pembrolizumab + trastuzumab Sensitive: A1 - Approval pembrolizumab + trastuzumab Sensitive : A1
BRAF V600E	Colorectal Cancer	BRAF V600E	Colorectal Cancer	cetuximab + encorafenib Sensitive: A1 - Approval cetuximab + encorafenib Sensitive : A1	cetuximab + encorafenib Sensitive: A1 - Approval cetuximab + encorafenib Sensitive : A1
No biomarker	Colon Cancer	No biomarker	Colon Cancer	capecitabine Sensitive: A1 - Approval capecitabine Sensitive : A1	capecitabine Sensitive: A1 - Approval capecitabine Sensitive : A1
No biomarker	Rectal Cancer	No biomarker	Rectal Cancer	FOLFIRI Sensitive: A1 - Approval FOLFIRI Sensitive : A1	FOLFIRI Sensitive: A1 - Approval FOLFIRI Sensitive : A1
No biomarker	Colon Cancer	No biomarker	Colon Cancer	5-fluorouracil + irinotecan Sensitive: A1 - Approval 5-fluorouracil + irinotecan Sensitive : A1	5-fluorouracil + irinotecan Sensitive: A1 - Approval 5-fluorouracil + irinotecan Sensitive : A1
PD-L1 expression	Esophageal Squamous Cell Carcinoma	PD-L1 expression	Esophageal Squamous Cell Carcinoma	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
No biomarker	Colorectal Cancer	No biomarker	Colorectal Cancer	bevacizumab Sensitive: A1 - Approval bevacizumab Sensitive : A1	bevacizumab Sensitive: A1 - Approval bevacizumab Sensitive : A1
HER-2 negative + PD-L1 expression	Gastroesophageal Junction Adenocarcinoma	HER-2 negative + PD-L1 expression	Gastroesophageal Junction Adenocarcinoma	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
HER-2 negative + PD-L1 expression	Gastroesophageal Junction Adenocarcinoma	HER-2 negative + PD-L1 expression	Gastroesophageal Junction Adenocarcinoma	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
HER-2 negative + PD-L1 expression	Gastric Cancer	HER-2 negative + PD-L1 expression	Gastric Cancer	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
HER-2 overexpression	Gastric Cancer	HER-2 overexpression	Gastric Cancer	trastuzumab Sensitive: A1 - Approval trastuzumab Sensitive : A1	trastuzumab Sensitive: A1 - Approval trastuzumab Sensitive : A1
No biomarker	Esophageal Cancer	No biomarker	Esophageal Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
No biomarker	Gastroesophageal Junction Adenocarcinoma	No biomarker	Gastroesophageal Junction Adenocarcinoma	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	trastuzumab-qyyp Sensitive: A1 - Approval trastuzumab-qyyp Sensitive : A1	trastuzumab-qyyp Sensitive: A1 - Approval trastuzumab-qyyp Sensitive : A1
HER-2 overexpression	Gastric Cancer	HER-2 overexpression	Gastric Cancer	trastuzumab-qyyp Sensitive: A1 - Approval trastuzumab-qyyp Sensitive : A1	trastuzumab-qyyp Sensitive: A1 - Approval trastuzumab-qyyp Sensitive : A1
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	trastuzumab-dttb Sensitive: A1 - Approval trastuzumab-dttb Sensitive : A1	trastuzumab-dttb Sensitive: A1 - Approval trastuzumab-dttb Sensitive : A1

Gastrointestinal Cancer

Associations(2905)

Associations
(2905)